Innoviva’s antibiotics are growing 45%, so why did the company report a $73.9m loss?
Innoviva reported strong growth in its infectious disease and critical care medicines, supported by increasing XACDURO sales and the commercial launch of Nuzolvence. However, a substantial non-cash decline in the value of healthcare investments produced a quarterly net loss despite improving operating profitability.